Core Viewpoint - Kangzhi Pharmaceutical has recently announced its participation in the centralized procurement of chemical drugs led by Hebei Province, successfully winning the bid for its product, Levocetirizine Hydrochloride Granules [1] Group 1 - The selected result will be officially implemented on March 1, 2026 [1] - The procurement cycle for the selected drugs is two years, with procurement agreements signed annually during this period [1]

Group 1 - Haike Xinyuan signed a long-term cooperation agreement with BYD Lithium Battery to supply at least 100,000 tons of products annually for three years [1] - The products include four types of solvents: Dimethyl Carbonate (DMC), Ethylene Carbonate (EC), Ethyl Methyl Carbonate (EMC), and Diethyl Carbonate (DEC) [1] Group 2 - Aft announced plans to acquire equity in Shanghai Shengpu Fluid Equipment Co., Ltd. through a combination of share issuance and cash payment [2] - The stock of Aft will be suspended from trading starting January 27, 2026, for up to 10 trading days [2] - Shanghai Shengpu specializes in precision fluid control equipment and had previously withdrawn its IPO application [2] Group 3 - Conch Cement plans to invest in financial products with a maximum daily balance of 50 billion yuan, including 30 billion yuan in structured deposits and 20 billion yuan in bank wealth management products [3] - The actual purchases will depend on the safety and profitability of the underlying assets [3] Group 4 - Zijin Mining intends to acquire 100% of Allied Gold Corporation for approximately 28 billion yuan, with a price of 44 CAD per share [4] - Allied Gold's core assets include several gold mines and a projected gold resource of 533 tons [4] - The expected gold production from Allied Gold is 10.7 tons in 2023, increasing to 25 tons by 2029 [4] Group 5 - SanSheng GuoJian expects a net profit of around 2.9 billion yuan in 2025, a 311.35% increase year-on-year [5] - Duofluor expects a net profit of 20 to 28 million yuan in 2025, recovering from a loss of 30.8 million yuan in the previous year [5] - Chunzong Technology anticipates a net profit of 265 to 290 million yuan in 2025, a growth of 208.86% to 238.00% [5]

Group 1: Profit Forecasts - Shenling Environment expects a net profit of 205 million to 246 million yuan for 2025, representing a year-on-year increase of 77.39% to 112.87% [1] - Meinuohua anticipates a net profit of 100 million to 123 million yuan for 2025, an increase of 49.69% to 84.11% compared to the previous year [2] - Suotong Development forecasts a net profit of 730 million to 850 million yuan for 2025, reflecting a year-on-year increase of 167.98% to 212.03% [3] - Aikelan projects a net profit of 75 million to 100 million yuan for 2025, indicating a growth of 50.37% to 100.49% [3] - Hengyu Environmental expects a net profit of approximately 35.56 million yuan for 2025, a year-on-year increase of about 104.14% [4] - Yixin Tang anticipates a net profit of 260 million to 330 million yuan for 2025, representing a growth of 127.79% to 189.12% [6] - Yinlong Co. expects a net profit increase of 40% to 60%, projecting 331 million to 379 million yuan for 2025 [12] - Beite Technology forecasts a net profit of 11.5 million to 12.5 million yuan for 2025, reflecting a year-on-year increase of 60.98% to 74.98% [14] - Ha Li Co. anticipates a net profit of 65 million to 78 million yuan for 2025, representing a growth of 92% to 130% [33] - Ji Xin Technology expects a net profit of 115 million to 169 million yuan for 2025, indicating an increase of 277.15% to 454.09% [48] Group 2: Loss Forecasts - Chip Source Micro anticipates a net profit decrease of 62.53% to 74.36%, projecting 52 million to 76 million yuan for 2025 [8] - Lanhua Ketech expects a net loss of 440 million to 550 million yuan for 2025, indicating a shift from profit to loss compared to the previous year [13] - *ST Tianshan forecasts a net loss of 16 million to 23 million yuan for 2025, potentially triggering financial delisting [18] - Pingao Co. anticipates a net loss of 54 million to 44 million yuan for 2025, although this represents a narrowing of losses compared to the previous year [19] - Jianglong Boat expects a net loss of 90 million to 120 million yuan for 2025, a significant decline from the previous year's profit of 11.25 million yuan [20] - Li Guo Chemical anticipates a net loss of 410 million to 480 million yuan for 2025 [21] - Weichuan Technology expects a net loss of 110 million to 140 million yuan for 2025, although this reflects a narrowing of losses compared to the previous year [42] Group 3: Other Notable Announcements - Wan Tai Bio's bivalent HPV vaccine passed the WHO PQ periodic review, aiding its international market expansion [7] - Xian Da Co. received a supplier designation from a well-known international automotive manufacturer [47] - Heng Rui Pharmaceutical received clinical trial approval for its SHR-1049 injection, an innovative anti-tumor drug [15] - Qian Jin Pharmaceutical's subsidiary obtained a drug registration certificate for aluminum magnesium carbonate chewable tablets [16] - New Nuo Wei's subsidiary SYS6090 injection received clinical trial approval, targeting advanced solid tumors [36]

Core Viewpoint - Kangzhi Pharmaceutical (300086.SZ) has recently participated in the centralized procurement of chemical drugs led by Hebei Province, successfully winning the bid for its product, Levocetirizine Hydrochloride Granules [1] Group 1: Product Details - The selected product is Levocetirizine Hydrochloride Granules, with a specification of 2.5mg [2] - The product is indicated for conditions such as measles, allergic rhinitis, eczema, dermatitis, and pruritus [2] Group 2: Procurement Information - The selected price for Levocetirizine Hydrochloride Granules is 36.24 yuan per box [2] - The agreed first-year procurement volume is approximately 729,299 bags for Hebei and 1,006,393 bags for Jiangxi [2]

Core Viewpoint - Kangzhi Pharmaceutical (300086.SZ) has been selected for the centralized procurement of its product, Levocetirizine Hydrochloride Granules, in Hebei Province, which is expected to enhance market sales and share, positively impacting the company's long-term development [1] Group 1: Product and Procurement Details - The selected product specification is 2.5mg, indicated for conditions such as urticaria, allergic rhinitis, eczema, dermatitis, and pruritus [1] - The procurement results will be officially implemented on March 1, 2026, with an annual signing during the procurement cycle [1] Group 2: Market Impact and Uncertainties - The selection is anticipated to expand the market sales of the selected product and increase market share [1] - However, the related procurement contract has not yet been signed, leading to uncertainties regarding the actual progress and its impact on the company's future performance [1]